The Bragg peak of the proton beam has been used to treat 571 patients with pituitary-related disease. The method is associated with no mortality, low morbidity, short hospital stay and low cost.
slightly simpler than that employed by Kjellberg et al. (1972) . This dose is somewhat less than that employed by Kjellberg, but is well within the effective doses for pituitary ablation quoted for irradiation with a deuteron beam by Lawrence et al. (1970) .
Of the pituitary tumours, 254 procedures were done for acromegaly, 56 for Cushing's disease, and 44 chromophobe adenoma. The normal pituitary was irradiated in 183 instances for treatment of diabetic retinopathy and 35 procedures were done for carcinoma of the breast or prostate.
Normally, 12 portals of entry of beams are used on the two sides of the head, converging upon the sella turcica. The patient's head is secured in a stereotactic instrument applied under local anaesthesia with skeletal fixation. X-rays confirm the alignment of the proton 'beam spot' within the sella turcica. A beam diameter is selected for hyperfunctioning pituitary tumours to leave a shell of normal pituitary gland to preserve normal anterior and posterior lobe functions. Radionecrosis is induced in the central core of the tumour or gland. The dose along the beam path, for example, with a 10 mm beam diameter and 7000 rad to the pituitary tumour, is 300 rad, but most of the brain receives no radiation. The Bragg peak, the end of range of the proton beam, is about twice the path dose and stops within the pituitary. Measurements are made to fractions of a millimetre.
The entire procedure requires 1I to 2 hours during which time the patient is alert and cooperative. He walks away from the procedure and leaves the hospital the second day to return to home and occupation.
In acromegalics, mild headache is occasionally observed in the days following therapy. In 3 to 6 months, the patient's rings and heels of slippers become loose. In 6 to 12 months, the diminution in size of digits and facial features is obvious. One year afterward the HGH may be 10 ng/ml, but it will probably fall further during the second year. Glucose intolerance becomes normalized. The patient often expresses gratification over his restoration of vitality and joie de vivre. He is less often impressed because he continues to preserve normal pituitary function. The prospect of recurrent acromegaly is not a problem.
In Fig 1 box at the top right ofthefigure somewhat above 10 ng/ml, but these had fallen by 60-95 % of their preoperative values. Careful clinical appraisal is equally important in evaluation to laboratory figures. Roughly half of the remissions occur in the first year following therapy. Most of the remainder occur during the second year.
Results have improved and complications have been reduced with added experience. The most frequent complication, temporary oculomotor disturbance, has been reduced in frequency to 6 % in the last 50 patients. Temporary field defects, but no blindness, occurred in 5 patients, 3 of which were in the first 50 patients treated. Eightyfive per cent of treated patients preserve normal pituitary function. A few minor seizures (no grand-mal), relieved by diphenylhydantoin, occurred in 4 patients.
In Cushing's disease the results of proton hypophysectomy are similar to those in acromegaly with a slightly higher frequency of satisfactory results (89 %) and a slightly lower frequency of complications. This group of patients is particularly gratifying in that they are usually not cortisone-dependent, making them more satisfactory than adrenalectomized patients. Eight of these patients with Nelson's syndrome have been treated: 7 of them are partially depigmented, and none has required further therapy for pituitary tumour.
Patients with chromophobe adenoma, excluding our early experience , have had uniformly satisfactory results and no complications.
We exclude from proton beam therapy all patients with suprasellar extension of tumour or excess prior X-radiation therapy. We strongly favour transsphenoidal hypophysectomy by the method of G Guiot and J Hardy over transfrontal craniotomy because it has substantially lower lethal risk and, in our hands, no visual complications.
The hospitalization costs average $1500 (£.600) for proton hypophysectomy, less than one-third that of frontal craniotomy, thus saving $3500 (£L400). Considering the efficiency and economy of air travel, one such cyclotron facility can easily serve the needs of a large area such as half the United States or all of the United Kingdom. The association of hypogonadism and anosmia, and the familial occurrence of the syndrome, was described in 1944 (Kallmann et al. 1944) . The hypogonadism is thought to be secondary to hypothalamic dysfunction and deficient secretion of luteinizing hormone releasing hormone, LHRH (Naftolin et al. 1971 ). Nevertheless, most patients have plasma gonadotrophin concentrations in the prepubertal range (Bardin et al. 1969 , Boyar et al. 1973 ) and although the patients are hypogonadal, they have normal sexual differentiation and usually have normal testicular descent.
We report a family in which there was a high incidence of cryptorchidism. Consideration of the cases suggests that low fetal gonadotrophin secretion may cause cryptorchidism and that gonadotrophin secretion is involved in the mechanism by which cryptorchid testes are damaged in adult life. The family pedigree is shown in Fig 1. Five of the 6 affected males who were examined were cryptorchid. The sisters of F G and S A, including two known carriers, had normal olfactory thresholds, assessed by the method of Henkin & Bartter (1966) . Plasma gonadotrophins were measured using a double antibody technique (Midgley 1966) using 2nd IRP-HMG standard and antisera provided by Dr C A Paulsen (LH) and Dr W Butt (FSH). Case 1 F G. Presented aged 19 with hypogonadism and cryptorchidism. He had mild hypertension, and an intravenous pyelogram and cystoscopy showed an absent left kidney and no left ureteric opening. Recent testing showed anosmia to pyridine and nitrobenzene. Male secondary sexual characteristics developed following treatment with methyltestosterone. At age
